Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Chart: The Economist GLP-1 drugs are already having a huge impact in the pharma industry, with a large number of new drugs in the pipeline (see chart). But many other sorts of business are also ...

The uptake of GLP-1 has surged since 2022, mainly in US. Read our takeaways from the UBS Evidence Lab survey on key trends in GLP-1 consumer behaviour GLP-1s, also known as glucagon-like peptide 1, ...